Company
(Symbol)^#
(M)

Type Of
Financing

Number Of
Shares, Units
Or Warrants

Amount
Raised
(M)

Investors; Placement Agents; Details (Date)^@

Accentia Bio-
Pharmaceuticals
Inc. (ABPI)

Convertible debenture financing

N/A

$20

Accentia entered an agreement for a four-year term, $20M convertible debenture financing with several institutional investors (2/28)

Active Biotech
AB (Sweden;
SSE:ACTI)

Preferential rights issue

N/A

SEK240 (US$34.7)

The issue was oversubscribed by 53% and it increased the company's outstanding shares to 44M (2/14)

Adherex
Technologies
Inc. (AMEX:ADH;
TSX:AHX)

Private placement of units

75.8U

$25

The sale consists of 30.3M units at 33 cents per unit, and up to 45.46M additional units; each unit consists of one common share and half a warrant; Versant Partners Inc. is purchasing the shares (2/14)

Antares
Pharma Inc.
(AMEX:AIS)

Secured credit facility

N/A

N/A

Antares closed a facility consisting of two term loans that total $10M; the lenders are MMV Financial Inc. and HSBC Capital (Canada) Inc.; Antares also issued warrants to the lenders to purchase 640,000 shares at $1.25 per share (2/28)

Ariad
Pharmaceuticals
Inc. (ARIA)

Equity financing commitment

N/A

N/A

Ariad secured a commitment from Azimuth Opportunity Ltd. for up to $50M of the company's stock over the next 18 months (2/15)

Bavarian
Nordic A/S
(Denmark;
CSE:BAVA)

Rights issue

1.28S

DKK465 (US$82)

Bavarian Nordic raised $82M through the rights issue of 1.28M new shares at DKK365 per share; underwriters are FIH Erhvervsbank A/S and Nordea Bank Danmark A/S (2/21)**

Bio-Bridge
Science Inc.
(OTC BB:BGES)

Private placement of Series A convertible preferred stock and warrants

4S and 3W

$3

The warrants are immediately exercisable at $1 per share and are exercisable at any time within three years from the date of issuance (2/13)

Cell
Therapeutics
Inc. (CTIC)

Private placement of preferred stock and warrants

N/A

$17.6

Cell Therapeutics is selling $17.6M of 3% convertible preferred stock and warrants in an offering to institutional investors; the stock will be convertible into about 10.55M common shares at $1.6725 per share; investors also will get warrants to purchase up to 5.27M shares of common stock at $1.61 per share; Rodman & Renshaw LLC is exclusive placement agent (2/9)

ChemGenex
Pharmaceuticals
Ltd. (Australia;
CXSP)

Private placement of shares and options

17S and 5.7 options

$8.2

ChemGenex priced 17M new shares at 48 cents each and the 5.7M options will have a five-year term and an exercise price of 58 cents; investors were Alta Partners, GBS Venture Partners and others (2/8)

Chromos
Molecular
Systems Inc.
(Canada;
TSX:CHR)

Private placement of units

ND

C$8 (US$6.8)

Each unit will include one common share and half a warrant and are being sold at 15 cents each; each five-year whole warrant entitles the holder to purchase one share at C20 cents each; the deal is co-led by Dundee Securities Corp., Canaccord Capital Corp. and Clarus Securities Inc. (2/2)

Clinical Data
Inc. (CLDA)

Share exercise

0.19S

$3.7

Clinical Data raised about $3.7M through the exercise of 190,505 shares at $19.45 per share; they were exercised by affiliates of Chairman R.J. Kirk, which received them in connection with a $17M private placement in June (2/28)

Cyclacel
Pharmaceuticals
Inc. (CYCC)

Private placement of stock and warrants

4.2S and 1.1W

$36

Cyclacel sold units consisting of about 4.2M shares and 1.1M warrants to institutional investors; Lazard Capital Markets LLC served as lead placement agent, while Needham & Co. LLC and Think- Equity Partners LLC were co-agents (2/13)

Cytori
Therapeutics
Inc. (CYTX)

Registered direct offering

ND

$21.5

Cytori raised the money by offering common stock and warrants (2/26)

Devgen NV
(Belgium;
BR:DEVG)

Private placement of common stock

1.5S

€31 (US$40.7)

Devgen raised $40.7M placing 1.5M shares with institutional investors at €20.75 each (2/15)

DOR
BioPharma
Inc. (OTC BB:
DORB)

Private placement of common stock

11.68S

$5.5

DOR sold 11.68M shares at 47 cents per share to institutional investors, members of senior management and directors (2/9)

Encysive
Pharmaceuticals
Inc. (ENCY)

Private placement of nonconvertible notes

ND

$60

The money was raised through the sale of 12% notes that mature in September 2014 (2/7)

Enzo Biochem
Inc. (NYSE:ENZ)

Registered direct offering

1S

$15

Enzo raised the money through the offering with an undisclosed buyer; Lazard Capital Markets LLC served as exclusive placement agent (2/5)

ExonHit
Therapeutics
SA (France;
Euronext:ALEHT)

Private placement of common stock

0.4S

€2.9 (US$3.9)

ExonHit issued 400,000 shares following the exercise of a tranche of the Pacea line signed between Societe Generale Corporate & InvestmentBanking and the company in October 2006 (2/26)

Favrille Inc.
(FVRL)

Private placement of common stock

3.3S

$9.9

Investors are MPM BioEquities Adviser LLC and Federated Kaufmann Fund (2/13)

GammaCan
International
Inc. (Israel;
OTC BB:GCAN)

Private placement of common stock and warrants

16.3S and W

$6.5

GammaCan completed a $6.5M private placement with a group of investors led by T.R. Winston & Co. LLC; the company issued 16.3M shares at 40 cents each and warrants equal to the amount of shares, exercisable at 48 cents each (2/28)

Genelabs
Technologies
Inc. (GNLB)

Private placement of common stock and warrants

5.8S and W for 1.7S

$10

Genelabs sold about 5.8M shares and warrants to buy 1.7M shares to institutional and accredited investors; Oppenheimer & Co. Inc. acted as the placement agent (2/15)

Gentium SpA
(Italy; GENT)

Private placement of American depositary shares

2.354S

$47.5

Gentium sold the shares at $20.17 per ADS; ThinkEquity Partners LLC was the exclusive placement agent (2/7)

Geron Corp.
(GERN)

Warrant exercise

W for 1.875S

$15

Geron raised $15M through the purchase of shares at $8 apiece; the warrants were issued to institutional investors in connection with a $40M financing announced in December (2/27)

Glycotex Inc.
(subsidiary of
Novogen Ltd.;
Australia; NVGN)

Private placement of common stock

N/A

$1.6

Glycotex received the first tranche of a private placement; investors received shares totaling 3.6% of Glycotex; Novogen retained an 81.3% interest in the company (2/27)

IDM Pharma
Inc. (IDMI)

Private placement of common stock and warrants

4.5S and W for 0.78S

$12.8

IDM raised $12.8M placing 4.5S at $2.82 each and issuing warrants to purchase about 782,500 additional shares at 2.2 cents per share, with an exercise price of $3.243 per share (2/21)

Illumina Inc.
(ILMN)

Private placement of convertible senior notes

N/A

$400

Illumina offered $400M in notes due 2014 to qualified institutional buyers (2/13)

Immtech
Pharmaceuticals
Inc. (AMEX:IMM)

Registered direct offering

1S

$6.75

Ferris Baker Watts Inc. acted as the exclusive placement agent (2/8)

Isotechnika Inc.
(Canada; TSX:ISA)

Bought-deal financing

21.9U

C$40.4 (US$34.5)

Isotechnika's offering includes the underwriters' full exercise of about 2.9M units, each consisting of one common share and a purchase warrant for half a share; each whole warrant will entitle the holder to purchase one share for two years after the deal closes at C$2.40; underwriters were GMP Securities LP, Cannacord Capital Corp., RBC Dominion Securities and National Bank Financial Inc. (2/20)

Kosan
Biosciences
Inc. (KOSN)

Registered direct offering

7S

$45.5

Kosan is selling 7M shares to institutional investors at $6.50 per share; Cowen and Co. LLC is lead placement agent; co-placement agents are Leerink Swann & Co. and Rodman & Renshaw LLC (2/9)

Medarex Inc.
(MEDX)

Private sale of Genmab shares

2.5S

$150

Medarex raised about $150M through the sale of 2.5M shares of Genmab A/S, of Copenhagen, Denmark; the sale reduces Medarex's ownership to 11% (2/20)

MediGene AG
(Germany;
BE:MDG)

Private placement of common stock

2.1S

€12.6 (US$16.6)

MediGene closed a capital increase of about $16.6M; the sole lead manager, DZ Bank, subscribed to 2.1M shares and offered them to institutional investors in Germany and Europe at €6.10 per share (2/15)

Medivir AB
(Sweden; SSE:
MVIRB)

Rights issue

N/A

SEK224.5 (US$32)

Carnegie Investment Bank was financial adviser and shares are expected to begin trading Feb. 28 (2/7)

MethylGene
Inc. (Canada;
TSX:MYG)

Bought-deal financing

5.5S

C$20 (US$17.3)

MethylGene agreed with a syndicate of under- writers led by Canaccord Capital Corp. to sell on a bought-deal basis 5.5M shares, which will then be sold to the public at $3.65 per share; the under- writers have an overallotment option for another 825,000 shares (2/13)

Microbix
Biosystems
Inc. (Canada;
TSX:MBX)

Private sale of a 9% convertible debenture

N/A

C$0.5 (US$0.43)

Microbix raised $430,000 through the sale of the debenture to an existing shareholder; the principal amount is convertible into common shares at C90 cents per share for 10 years (2/20)

Nuvo Research
Inc. (Canada;
TSX:NRI)

Warrant incentive plan

19.55W

C$7.9 (US$6.7)

Nuvo raised the money through the exercise of 19.55M warrants (2/9)

Oncolytics
Biotech Inc.
(Canada; ONCY;
TSX:ONC)

Private placement of stock and warrants

4U

C$12 (US$10)

Oncolytics raised $10M issuing 4M units comprised of one common share purchase warrant at C$3 apiece (2/6)

Pluristem
Life Systems
Inc. (OTC BB:
PLRS)

Private placement of common stock

N/A

$8

Pluristem signed a binding term sheet with investors to raise $8M through the sale of common stock at 1 cent per share and a warrant to purchaseadditional shares at 2.5 cents each (2/14)

Point
Therapeutics
Inc. (POTP)

Private placement of stock and warrants

6.52S and W for .98S

$4.76

The five-year warrants can be exercised at $1 each; Federated Kaufmann Fund participated in the transaction; Rodman & Renshaw LLC was the sole placement agent (2/2)

pSivida Ltd.
(Australia;
PSDV; ASX: PSD)

Private placement of common stock

50S

A$11.5 (US$9)

pSivida raised $9M, selling 50M shares at A$0.23 per share; HPC Capital Management Corp. is the placement agent (2/20)

ReNeuron
Group plc
(UK; LSE:RENE)

Private placement of new ordinary shares

18.3S

£5.5 (US$10.7)

ReNeuron sold the shares at 1 pence each; Collins Stewart Europe Ltd. acted as nonimated adviser and broker (2/14)**

Salix
Pharmaceuticals
Ltd. (SLXP)

Credit facility

N/A

N/A

Salix entered a credit facility with Bank of America NA for up to $100M; the company has borrowed $15M so far (2/28)

Stem Cell
Therapeutics
Corp. (Canada;
CDNX:SSS)

Private placement of units

10U

C$2 (US$1.7)

Stem Cell Therapeutics sold 10M units, each consisting of one share and one-half of a warrant; each full warrant entitles the holder to purchase one common share at C25 cents for two years (2/2)

Symbollon
Pharmaceuticals
Inc. (OTC BB:
SYMBA)

Private placement of common stock and warrants

3.21S and 2.4W

$2.37

Symbollon raised net proceeds of $2.37M selling 3.21M Class A common shares and 2.4M warrants (2/14)

Toxin Alert
Inc. (Canada;
CDNX:TOX)

Private placement of units

0.4U

C$0.24 (US$0.21)

Toxin Alert raised $206,706 by privately placing 400,000 units, each consisting of one common share and one nontransferable warrant to purchase additional shares, priced at C60 cents each (2/22)

Vion
Pharmaceuticals
Inc. (VION)

Private placement of convertible senior notes and warrants

Notes and W for 7.8S

$60

Vion agreed to sell up to $60M in notes due 2012 and warrants to purchase up to 7.8M shares (2/14)

Ziopharm
Oncology Inc.
(ZIOP)

Private placement of units

5.9S and W for 1.2S

$30.9

Ziopharm raised $30.9M by placing units, comprised of one share and a warrant to buy 0.2 shares; the financing was led by Essex Woodlands Health Ventures and PTV Sciences, with participation from ProQuest Investments, LB I Group Inc., Henderson Global Investors and two funds - Medical BioHealth Trends and Pharmaw/Health - advised by Medical Strategy; Oppenheimer & Co. Inc. served as the lead placement agent, while Paramount BioCapital Inc. and Griffin Securities Inc. acted as co-placement agents (2/19)